Female sexual dysfunction (FSD) incorporates various sexual disorders including hypoactive sexual desire disorder, sexual arousal disorder, orgasmic and sexual pain disorders. Although many strategies have been formulated for the treatment of male sexual problems, FSD remains an area that warrants further research and trial studies to identify the most efficacious treatment options. Research has highlighted numerous pharmacological interventions that have been trialled and found to exhibit positive effects. These include hormonal therapies, prostaglandins, dopaminergic agonists, phosphodiesterase type-5 (PDE-5) inhibitors and melanocortin agonists.
BermanJR. Physiology of female sexual function and dysfunction. Int J Impot Res2005;17:S44–51
2.
GoldmeierD, LeiblumSR. STIs and sexual dysfunction. Sex Transm Infect2005;81:364
3.
BrownAD, BlaggJ, ReynoldsDS. Designing drugs for the treatment of female sexual dysfunction. Drug Discov Today2007;12:757–66
4.
BassonR. Women's sexual dysfunction: revised and expanded definitions. CMAJ2005;172:1327–33
5.
WylieK, MimounS. Sexual response models in women. Maturitas2009;63:112–15
6.
BermanJR, Female sexual dysfunction: anatomy, physiology, evaluation and treatment options. Curr Opin Urol1999;9:563–8
7.
ButcherJ. ABC of sexual health: female sexual problems II: sexual pain and sexual fears. BMJ1999;318:110–2
8.
KaplanC. Assessing and managing female sexual dysfunction. Nurse Pract2009;34:42–8
9.
WylieKR. Sexuality. In: PawsonM, CockburnJ, eds. Psychological Challenges in Obstetrics and Gynecology. The Clinical Management. London: Springer, 2007
10.
WylieKR, DainesB, JanniniEA, Loss of sexual desire in the postmenopausal woman. J Sex Med2007;4:395–405
11.
FrankJR, MistrettaP, WillJ. Diagnosis and treatment of female sexual dysfunction. Am Fam Physician2008;77:635–42
12.
WiermanME. Sex steroid effects at target tissues: mechanisms of action. Adv Physiol Educ2007;31:26–33
13.
HoflandSL, PowersJ. Sexual dysfunction in the menopausal woman: hormonal causes and management issues. Geriatr Nurs1996;17:161–5
14.
Castelo-BrancoC, CanceloMJ, ChedrauiP. Female sexual dysfunction in postmenopausal women. Expert Opin Ther Patents2007;17:1–10
15.
GregersonN, JensenPT, GiraldiAE. Sexual dysfunction in the peri- and postmenopause. Dan Med Bull2006;53:349–53
16.
CanonicoM, OgerE, Plu-BureauG, Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: The ESTHER Study. Circulation2007;115:840–5
17.
Barrett-ConnorE, GradyD. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health1998;19:55–72
18.
ArltW. Androgen therapy in women. Eur J Endocrinol2006;154:1–11
DavisonSL, BellR, DonathS, MontaltoJG, DavisSR. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab2005;90:3847–53
21.
DavisSR, MoreauM, KrouR, Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med2008;359:2005–17
22.
BraunsteinGD, SundwallDA, KratzM, Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med2005;165:1582–9
23.
ShufeltCL, BraunsteinGD. Testosterone and the breast. Menopause Int2008;14:117–22
24.
SchoverLR. Androgen therapy for loss of desire in women: is the benefit worth the breast cancer risk?Fertil Steril2008;90:129–40
25.
SimonJ, BraunsteinG, NachtigallL, Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab2005;90:5226–333
26.
BuvatJ. Androgen therapy with dehydroepiandrosterone. World J Urol2003;21:346–55
27.
NijlandEA, Weijmar SchultzWC, Nathorst-BoösJ, LISA Study Investigators. Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial. J Sex Med2008;5:646–56
28.
GoldsteinI, LueT, Padma-NathanH, RosenR, SteersW, WickerP. Oral sildenafil in the treatment of erectile dysfunction: Sildenafil Study Group. N Engl J Med1998;338:1397–404
29.
GhofraniHA, OsterlohIH, GrimmingerF. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov2006;5:689–702
30.
GragasinFS, MichelakisED, HoganA, The neurovascular mechanism of clitoral erection: nitric oxide and cGMP-stimulated activation of BKCa channels. FASEB J2004;18:1382–91
31.
BermanJ, BermanL, TolerS, GillJ, HaughieS. Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double-blind, placebo controlled study. J Urol2003;170:2333–8
32.
FultonCW. Female Sexual dysfunction. US Pharm2006;10:57–64
33.
SchoenC, BachmannG. Sildenafil citrate for female sexual arousal disorder: a future possibility?Nat. Rev Urol2009;6:216–22
34.
KielbasaLA, DanielKL. Topical Alprostadil Treatment of female sexual arousal disorder. Ann Pharmacother2006;40:1369–76
35.
RosenRC, PhillipsNA, GendranoNCIII, FergusonDM. Oral phentolamine and female sexual arousal disorder: a pilot study. J Sex Marital Ther1999;25:137–44
36.
DerzkoC, ElliotS, LamW. Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy. Curr Oncol2007:(Suppl. 1.)
37.
ModellJG, MayRS, KatholiCR. Effect of bupropion-SR on orgasmic dysfunction in nondepressed subjects: a pilot study. J Sex Marital Ther2000;26:231–40
38.
MasandPS, Keller AshtonA, GuptaS, FrankB. Sustained-release bupropion for selective serotonin reuptake inhibitor-induced sexual dysfunction: a randomized, double-blind, placebo-controlled, parallel-group study. Am J Psychiatry2001;158:805–7
39.
SegravesRT, ClaytonA, CroftH, WolfA, WarnockJ. Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women. J Clin Psychopharmacol2004;24:339–42
40.
GantzI, FongTM. The melanocortin system. Am J Physiol Endocrinol Metab2003;284:E468–74
41.
SafarinejadMR. Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study. European Urology Supplements. J Sex Med2008;5:887–97
42.
JollyE, ClaytonA, ThorpJ, Lewis-D'AgostinoD, WunderlichG, LeskoL. T09-P-05 Design of Phase III pivotal trials of flibanserin in female Hypoactive Sexual Desire Disorder (HSDD). Sexologies2008;17(Supp. 1):S133–4
43.
BrownAD, BlaggJ, ReynoldsDS. Designing drugs for the treatment of female sexual dysfunction. Drug Discov Today2007;12:757–66
44.
Castelo-BrancoC, CanceloMJ, ChedrauiP. Female sexual dysfunction in postmenopausal women. Expert Opin Ther Patents2007;17:1–10
45.
KrychmanML, GubiliMS, PereiraL, HolsteinL, CassilethB. Female sexual enhancers and neutraceuticals. Curr Sex Health Rep2007;4:177–82
46.
RowlandDL, TaiW. A Review of plant-derived and herbal approaches to the treatment of sexual dysfunctions. JSMT2003;29:185–205
